You are here

A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

Last updated on September 8, 2019

FOR MORE INFORMATION
Study Location
Aichi Cancer Center Hospital
Nagoya, Aichi, 464-8681 Japan
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Neoplasms
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
20-120 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histological or cytological diagnosis of locally advanced or metastatic solid tumor
that is resistant to standard therapy or for which no standard therapy is available.

- ECOG Performance Status 0 or 1.

- Adequate Bone Marrow, Renal and Liver Function.

- Able to take oral medications.

- Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1.

- Serum or urine pregnancy test (for females of childbearing potential) negative at
screening.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients with known symptomatic brain metastases requiring steroids.

- Major surgery within 4 weeks prior to the first dose of study treatment.

- Radiation therapy within 4 weeks prior to the first dose of study treatment.

- Any antitumor systemic cytotoxic therapies and/or treatment with immune modulators
within 4 weeks prior to the first dose of study treatment.

- Previous high dose chemotherapy requiring stem cell rescue.

- Prior irradiation to >25% of the bone marrow.

- Active and clinically significant bacterial, fungal, or viral infection

- Myocardial infarction within 6 months before starting therapy, symptomatic congestive
heart failure, unstable angina, or unstable cardiac arrhythmia requiring medication.

- Hypertension that cannot be controlled by medications.

- Participation in other studies involving investigational drug(s) within 4 weeks prior
to the first dose of study treatment.

- Other acute or chronic medical or psychiatric condition, or laboratory abnormality
that may increase the risk associated with study participation or investigational
product administration or may interfere with the interpretation of study results and
would make the patient inappropriate for entry into this study.

- Fertile male patients and female patients of childbearing potential who are unwilling
or unable to use 2 highly effective methods of contraception and for 180 days after
the last dose of investigational product.

- Breastfeeding at screening or at any time during study participation.

- Current use of a strong P-gp inhibitor, strong P-gp inducer, or strong inhibitor of
BCRP within 1 week or 5 half lives which ever is longer prior to the first dose of
study treatment.

NCT03343054
Pfizer
Not yet recruiting
A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Breast Neoplasms, Stomach Neoplasms, Esophagogastric Junction Neoplasm, Non-small-cell Lung Carcinoma
NCT03284723
All Genders
18+
Years
Multiple Sites
Lung Neoplasms
NCT03220230
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now